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Cell-free circulating DNA (cfDNA) released from dying cells is emerging as an 
important tool for the diagnosis of disease. Non-invasive prenatal testing (NIPT) 
detects fetal chromosomal aberrations using cfDNA in maternal blood, and 
information on somatic mutations in cancer can be used to monitor circulating tumor 
DNA as a marker of tumor dynamics. However, the utility of cfDNA is limited in 
conditions where injured tissues have a normal genome or mutations are not known. 
We present a method to identify the tissue origins of cfDNA, based on conserved 
tissue-specific methylation patterns that are retained in circulating DNA fragments. 
We used methylation markers of specific cell types to identify elevations in pancreatic 
beta-cell DNA in the circulation of recently diagnosed type 1 diabetes (T1D) patients 
and in islet graft recipients, brain DNA in the circulation of patients after traumatic 
brain injury or cardiac arrest, and oligodendrocyte DNA in the circulation of patients 
with multiple sclerosis during relapse. The approach offers a minimally-invasive 
window into the monitoring and diagnosis of human diseases involving cell death, as 





It has been known for decades that the plasma contains small fragments of cfDNA 
derived from dead cells (on average 5000 genome equivalents per ml) (1). While the 
mechanisms underlying the release and clearance of cfDNA remain obscure, the 
phenomenon is rapidly gaining applications. The recognition that fragments of fetal 
DNA travel briefly in maternal circulation has opened the way to next generation 
sequencing (NGS)-based prenatal testing to identify fetal trisomies and other genetic 
aberrations, potentially replacing amniocentesis (2-4). In cancer biology, tumors are 
known to release DNA (carrying tumor-specific somatic mutations) to the circulation, 
providing means for liquid biopsies to monitor tumor dynamics and evolution (5-7). 
cfDNA has also been used to detect graft cell death after kidney, liver or heart 
transplantation, based on single nucleotide polymorphisms (SNPs) distinguishing the 
DNA of donor from that of recipient (8-10). In all these cases, genetic differences 
exist between the DNA sequence of the tissue of interest (fetus, tumor or graft) and 
the host, providing the basis for highly specific assays. 
The levels of cell-free circulating DNA are known to increase in multiple additional 
conditions such as traumatic brain injury (11), cardiovascular disease (12), sepsis (13) 
and intensive exercise (14). However in these cases, the source of elevated cfDNA is 
not known (for example, it could originate from parenchymal cells of the injured 
tissue but also from dying inflammatory cells), which greatly reduces the utility of 
cfDNA as a diagnostic tool.  
 
Despite having an identical sequence, the DNA of each cell type in the body does 
carry unique epigenetic marks. In particular, DNA methylation is a fundamental 
aspect of tissue identity that is unique to each cell type, conserved among cells of the 
same type in the same individual and between individuals, and is highly stable under 
physiologic or pathologic conditions (15). Therefore, it should be possible to use the 
DNA methylation pattern of cfDNA to determine its tissue of origin and hence to 
infer cell death in the source tissue.  
Theoretically, such an approach could identify the rates of cell death in a tissue of 
interest, taking into account the total amount of cfDNA, the fraction derived from a 
tissue of interest, and the estimated half life of cfDNA (15-120 minutes) (16, 17). 
Note that since the approach relies on normal, stable markers of cell identity, it cannot 
identify the nature of the pathology (e.g. distinguishing cfDNA derived from dead 
tumor cells or dead wild type cells due to trauma or inflammation in the same tissue). 
 
One classic example of tissue-specific DNA methylation is provided by the insulin 
gene promoter, which is unmethylated in insulin-producing pancreatic beta-cells and 
methylated elsewhere. Recent studies have identified unmethylated insulin promoter 
DNA in the circulation of newly diagnosed T1D patients, reflective of autoimmune 
destruction of beta-cells, and in islet graft recipients (18-20). We sought to generalize 
the approach towards a proof of concept that tissue-specific methylation patterns in 
cfDNA can be used to detect tissue-specific cell death in multiple human pathologies.   
 
 
Identification of tissue-specific methylation markers  
 
We started by establishing tissue-specific DNA methylation markers, distinguishing 
individual tissues or cell types from other tissues. Particular attention was given to 
markers that differ between a tissue of interest and blood, which is thought to be the 
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main contributor of cfDNA and hence is a major potential source of noise in the 
system. We analyzed publicly available methylomes (mostly Illumina 450k array data 
from The Cancer Genome Atlas [TCGA]) to identify individual CpG dinucleotides 
with tissue-specific methylation patterns (i.e. unmethylated or methylated specifically 
in one tissue and methylated or unmethylated elsewhere) (see schematic of procedure, 
Supplemental figure S1).  
 
The Illumina arrays provide information on the methylation status of individual CpG 
dinucleotides. The discriminatory power of each site is limited, since it can be 
randomly methylated or unmethylated in a small fraction of molecules from tissues 
where it is supposed to be methylated or unmethylated, respectively. For example, if a 
specific CpG site is methylated in 95% of beta-cells and 5% of blood cells, it will be 
difficult to identify beta-cell DNA embedded in blood DNA in a frequency smaller 
than 5%. To increase the signal to noise ratio of the assay we took advantage of the 
regional nature of DNA methylation. We defined an “expanded window” of 5-9 CpG 
sites adjacent to the original CpG marker site, reasoning that the chances are small for 
accidental methylation or demethylation of multiple adjacent cytosines in the same 
molecule. To determine the status of methylation of these expanded windows we 
obtained DNA from different human tissues, and treated with bisulfite to convert 
unmethylated cytosines to uracils. We then PCR-amplified short fragments containing 
the signature CpG site and multiple adjacent CpGs, and sequenced multiple molecules 
from the PCR product using Illumina MiSeq. As an alternative approach to the 
comparisons between Illumina methylome arrays, in some cases we selected and 
validated tissue specific markers based on promoters of tissue specific genes (which 
might have been absent from the Illumina arrays) (Supplemental Figure S1). As 
shown in the examples below, scoring for DNA molecules in which multiple adjacent 
CpG sites share the same tissue-specific methylation pattern gave a dramatically 
higher discriminatory power between the tissue of interest and other tissues, 
compared with the information content of individual CpG sites.  
Thus we have defined short sequences of DNA, containing 6-9 CpG sites, whose 
combined methylation status is typical to a tissue of interest relative to blood and 
other tissues.      
 
Unmethylated insulin gene promoter in the circulation of T1D patients 
        
To detect cfDNA derived from beta-cells, we used the insulin gene promoter as a 
beta-cell specific methylation marker. Previous studies have performed methylation-
specific PCR, based on the methylation status of 2 CpG dinucleotides in the insulin 
promoter, to identify DNA derived from beta-cells (19). However, the insulin 
promoter contains additional CpG sites in the same area, which theoretically can be 
used to better distinguish DNA of beta-cells and other tissues (Figure 1A). To test this 
idea, we amplified a 160bp fragment of the insulin gene promoter from bisulfite-
treated DNA obtained from multiple tissues, and sequenced the product to determine 
the methylation status of each CpG in each tissue. As shown in Figure 1B, each CpG 
was unmethylated in 90-95% of the DNA molecules from human beta-cells, and in 5-
15% of the DNA molecules from other tissues. However when we combined this 
information and calculated the fraction of DNA molecules in which all 6 CpG sites 
were unmethylated, the difference between beta cells and all other tissues became 
dramatically larger: while ~80% of DNA molecules from beta-cell were fully 
unmethylated, <0.01% of the molecules from any other tissue were fully 
 5 
unmethylated. Thus a stretch of 6 adjacent unmethylated CpG sites in the insulin gene 
promoter distinguishes beta-cells from other tissues with a signal to noise ratio close 
to 10,000:1. We next used this information to look for beta-cell derived DNA in the 
circulation of T1D patients. Plasma DNA from patients was treated with bisulfite, 
PCR amplified and sequenced to determine the fraction of molecules containing fully 
unmethylated insulin promoter DNA. The fraction obtained was multiplied by the 
concentration of cfDNA measured in each sample, to obtain a value of beta-cell 
derived DNA (ng/ml) circulating in the blood of each patient (Supplemental Figure 
S1).         
The cfDNA of healthy volunteers had an extremely low frequency of fully 
unmethylated insulin gene promoter molecules (<xxx% of circulating insulin 
promoter fragments). When multiplied by the total amount of cfDNA in each 
individual (Supplemental Figure S1), this suggested <0.01 ng/ml circulating DNA 
derived from beta-cells, consistent with a low background from non beta-cells, and a 
very low rate of beta-cell turnover in healthy adults (Figure 1C). T1D patients, 
sampled multiple times between 3 and 18 months after diagnosis, showed a clear 
signal of unmethylated insulin promoter DNA in cfDNA, indicative of ongoing 
autoimmune destruction of beta-cells (Figure 1D). Not surprisingly, the levels of beta-
cell-derived DNA greatly varied between patients, although we could not relate this 
variation to the levels of c-peptide or other recorded clinical parameters. Interestingly, 
while all patients showed evidence of abnormally high unmethylated insulin promoter 
DNA in the circulation, all had multiple measurements that were completely negative 
(that is, no unmethylated insulin promoter cfDNA above healthy baseline). The 
reason for the observed fluctuations of unmethyalted insulin in cfDNA remains to be 
elucidated. A fascinating possibility is that this is a reflection of the hypothesized 
remitting / relapsing nature of T1D (21). One feature of the data that did correlate 
with the clinical course of disease was that in several patients, the signal of 
unmethylated insulin appeared to decline eventually to baseline levels, likely 
reflecting loss of the vast majority of beta-cells. Note that at this time, all patients still 
had measurable c-peptide levels, indicative of remaining functional beta-cells. It will 
be important to determine if absence of beta-cell-derived cfDNA in c-peptide+ 
patients reflects tolerance of surviving beta-cells to immune destruction, or continued 
beta-cell killing at levels below the sensitivity limits of the assay. 
We also examined the circulation of long-time T1D patients that were transplanted 
with cadaveric allogeneic islets and treated with immune suppressants (22). As shown 
in Figure 1E, the plasma of all patients had a high signal (unmethylated insulin DNA) 
1-2 hours after transplantation, which dramatically declined in the hours and days that 
followed. The extensive loss of grafted beta-cells immediately after transplantation, 
potentially resulting from acute ischemia, is consistent with a previous imaging study 
of a transplanted patient (23). Note that in most patients, the signals detected at 7 days 
and even 1 month after transplantation were still clearly above background, 
suggesting continuous, low level killing of beta-cell despite immune suppression. 
To test if the combined methylation pattern of multiple CpG sites at the insulin gene 
promoter was necessary to detect beta-cell derived DNA in circulation, we examined 
the methylation status of each individual CpG in the plasma of healthy individuals 
and recently diagnosed T1D patients. Each individual CpG did not have a different 
pattern in the plasma of healthy controls and T1D patients (unmethylated in ~15% of 
cfDNA molecules). However combining the 6 CpG sites gave a clear signal in the 
plasma of T1D patients that was absent in healthy controls (Supplemental Figure S2).   
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These results support the utility of the NGS-based method for the detection of cfDNA 
derived from specific tissues. Specifically for T1D, they raise interesting questions 
about the dynamics of the disease which will be addressed elsewhere. 
 
Identification of oligodendrocyte-derived cfDNA in Multiple Sclerosis 
 
Non-invasive detection of brain cell death is particularly challenging. In theory, brain-
specific methylation patterns can be used to identify brain-derived cfDNA. We looked 
for evidence of oligodendrocyte DNA circulating in the blood of patients with 
multiple sclerosis (MS) and neuromyelitis optica (NMO), autoimmune diseases in 
which myelin-producing oligodendrocytes in the white matter are destroyed. We have 
analysed the published methylome of normal human white matter (24), and identified  
clusters of adjacent CpG sites in the promoter of Myelin Basic Protein 3 (MBP3) and 
around an un-annotated locus (CG10809560 in the Illumina array, which we termed 
WM1 for White Matter 1) which were unmethylated selectively in oligodendrocytes 
(Figure 2A). As with the insulin gene promoter, individual CpGs in these clusters 
showed a moderate signal to noise ratio: they were unmethylated in 60-85% of DNA 
molecules derived from sources rich for oligodendrocytes (glial preps, white matter 
and whole brain), and in 2-20% of DNA from other tissues (Supplemental Figures S3, 
S4). Combining all CpGs at the MBP3 and WM1 loci greatly increased the difference 
between DNA enriched for oligodendrocytes and DNA from other sources including 
blood (Supplemental Figures S3, S4). Thus DNA from the MBP3 or WM1 loci 
unmethylated in all adjacent CpG sites can serve as a marker of oligodendrocytes.    
Healthy individuals (n=12) had negligible levels of unmethylated MBP3 or WM1 in 
plasma, suggesting minimal basal turnover of oligodendrocytes (Figure 2B). Most 
remitting MS or NMO patients (n=11) had no or very low signal. However most 
patients during a relapse (documented using MRI close to the time of sampling, n=21) 
had in their plasma unmethylated DNA of either MBP3, WM1 or both (Figure 2B). 
This observation is consistent with the idea that short-lived circulating unmethylated 
MBP3 or WM1 DNA reflects acute oligodendrocyte cell death. Initial analysis did not 
reveal clinical correlates to the lack of signal in some relapsing patients.  
These results indicate that acute autoimmune destruction of oligodendrocytes can be 
detected as increased circulating levels of fully unmethylated DNA fragment from the 
MBP3 or WM1 loci. Additional methylation markers of oligodendrocyte can be 
developed to further increase the specificity and sensitivity of the assay.     
 
Identification of brain-derived cfDNA after acute brain damage   
       
To obtain a more general marker for brain injury, we scanned the Illumina arrays for 
loci whose methylation status distinguished brain DNA from other tissues. A cluster 
of 9 CpG sites around locus CG0978 was fully unmethylated in 70% of DNA from 
various sources of brain tissue (enriched for either neurons or glia), and in <5% of 
DNA molecules from other tissues (likely reflecting DNA of peripheral neurons 
present in these tissues). Importantly, <0.03% of molecules in blood were 
unmethylated, providing a >2000 fold difference in methylation between brain and 
blood (Figure 3A and Supplemental Figure S5).     
Healthy individuals had extremely low levels of fully unmethylated GC0978 in the 
plasma (Figure 3B). This low baseline may reflect either neuronal turnover below our 
sensitivity limit or an alternate mechanism of clearance of DNA from dead brain 
cells. We then examined plasma samples from patients in two settings of brain 
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damage, both known to involve neuronal injury in combination with disruption of the 
blood-brain barrier. Strikingly, patients (n=10) sampled at multiple time points after 
cardiac arrest with documented ischemic brain damage (25) showed high levels of 
unmethylated CG0978 in plasma (Figure 3C). Similarly, patients (n=5) hospitalized in 
a neurotrauma unit after suffering head injuries had elevated unmethylated CG0978 in 
plasma (Figure 3D). Both sets of results are consistent with circulating DNA 
fragments derived from dead brain cells (neurons and/or glia) in these patients. The 
amount and temporal patterns of brain-derived cfDNA varied between patients. In the 
group with cardiac arrest, the strongest signals were observed in the first time point, 
shortly after resuscitation, with a decline in subsequent days in most patients. In the 
group of patients with head trauma, a more delayed pattern of brain-derived cfDNA 
was observed. 
The absolute levels of cfDNA were elevated to a similar extent in both groups of 
patients compared with healthy controls, consistent with previous reports on cfDNA 
after traumatic brain injury (11) (Supplemental Figure S6). Interestingly, the levels of 
brain-derived cfDNA were much higher in patients with cardiac arrest, suggesting 
that the trauma patients had other, non-brain sources of extensive cell death 
(supplemental Figure S6).  
In summary, brain-specific DNA as well as oligodendrocyte-specific DNA can be 
identified in the circulation of patients with neuroinflammatory, traumatic and 
ischemic brain pathologies, based on unique methylation markers. More extensive 






The process of cell death in vivo remains largely inaccessible to non-invasive 
investigation and diagnosis. The approach proposed here relies on two well-
established principles in biology, namely that dying cells release cfDNA and that each 
tissue has a unique DNA methylation pattern. Combining these principles allows to 
identify the tissue origins of cfDNA and hence to assess the rate of cell death in 
tissues of interest. A unique feature of the method is the ability to detect cfDNA 
derived from tissues with normal genomes that are not accessible to mutation-based 
analysis of cfDNA. As a proof of principle we demonstrated the presence of tissue-
specific cfDNA in patients with T1D (beta-cell DNA), brain damage due to head 
injury or cardiac arrest (neuron/glia DNA), and multiple sclerosis (oligodendrocyte 
DNA). In all cases, a proportion of patients showed tissue-specific cfDNA at levels 
far above baseline. It remains to be seen why the measured levels of tissue-specific 
DNA in each pathology fluctuate so dramatically in all patients examined. This 
pattern may represent unrecognized oscillatory dynamics of cell death (e.g. 
fluctuations of autoimmune destruction of cells in T1D and MS), or alternatively a 
variation in the process by which DNA is released to, or cleared from the circulation. 
While the phenomenon calls for in depth investigation to understand the underlying 
biology, for practical purposes it may mean that cfDNA-based diagnosis will have to 
rely on samples obtained at multiple time points for each patient. 
 
Our current protocol searches for cfDNA derived from a specific tissue of interest 
based on one or few methylation markers of this tissue. This approach may have 
multiple applications, for example in the assessment of tissue damage after injury, in 
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the evaluation of cell death in response to therapy, and in the early diagnosis of 
diseases. In the long run, we envision a new type of blood test aimed at the sensitive 
detection of tissue damage without a-priori suspicion of disease. While such a tool 
can find a broad utility in diagnostic medicine, it will require first a deeper 
understanding of the rules that govern cfDNA dynamics, and baseline distribution of 
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Legends to figures 
 
 
Figure 1: beta cell-derived DNA in the circulation of T1D diabetes patients. 
A, structure of the insulin gene promoter fragment used as marker. Black dots 
represent CpG sites, arrows mark positions of PCR primers.  
B, methylation status of individual CpG sites in the insulin gene promoter in multiple 
tissues. Graph shows the percentage of unmethylated molecules in DNA from each 
tissue. Right columns describe the percentage of molecules in which all 6 CpG sites 
are unmethylated.  
C, beta-cell derived DNA in the plasma of healthy volunteers. The fraction of fully 
unmethylated insulin promoter DNA molecules (reflective of the fraction of beta-cell 
derived DNA) was multiplied by the absolute level of cfDNA measured in each 
individual. 
D, beta-cell derived DNA in the plasma of T1D patients, sampled at multiple time 
points after diagnosis. X axis, months from diagnosis; left Y axis (blue lines), 
concentration of beta-cell derived DNA in plasma (ng/ml); right Y axis (red), c-
peptide levels. 
E, beta-cell derived DNA in the circulation of long-time T1D patients sampled at the 
indicated time points after islet transplantation. 
 
 
Figure 2: identification of oligodendrocyte-derived cfDNA in multiple sclerosis 
A, methylation status of MBP1 and WM1 in multiple tissues. Note lack of 
methylation in total brain but not in neuron-rich cerebellum, suggesting that 
unmethylated molecules derived from glia. 
B, oligodendrocyte-derived DNA in the plasma of healthy volunteers, remitting and 
relapsing MS/NMO patients.  
 
 
Figure 3: identification of brain-derived cfDNA after brain damage. 
A, methylation status of CpG sites at the CG0978 locus in multiple tissues, as 
determined by deep sequencing. Bars represent the percentage of molecules in which 
all 9 CpGs of the locus are unmethylated. 
B, brain-derived DNA in the plasma of healthy volunteers, calculated by multiplying 
the fraction of fully unmethylated CG0978 by the amount of cfDNA in each 
individual. 
C, brain-derived DNA in the plasma of patients after cardiac arrest. Each  patient was 
sampled immediately after resuscitation (“acute”) and at different time points later. 
D, brain-derived DNA in the plasma of patients after traumatic brain injury, sampled 











Recently diagnosed T1D patients: 
 
Islet graft recipients: James 
 
MS/NMO patients: Adi. 
 
Cardiac arrest patients: The cardiac arrest samples were collected at the intensive 
care unit (ICU) at Uppsala University Hospital, Sweden. Unconscious patients with 
cardiac arrest were resuscitated with restoration of spontaneous circulation (ROSC). 
Hypothermia treatment to a body temperature of 32–34 ◦C for 24 h, ventilation, and 
pharmacologic support were administered immediately after resuscitation as 
described (Mörtberg E et al., Resuscitation 2011;82:26–31). Patients were defined as 
comatose if they were (i) not awake, (ii) not following any commands, and (iii) not 
responding to any stimuli. All patients received an arterial line in the radial or femoral 
artery for blood sampling. Serial blood samples were collected, starting as soon as 
possible in the emergency phase and continuing at 24, 48,72, 96 and 108 hours after 
cardiac arrest. Serum aliquots were frozen at −70◦C until analysis. The study was 
approved by the Ethics Committee at Uppsala University; informed consent was 
obtained from the closest relative. 
 
Traumatic brain injury: the 5 patients with traumatic brain injury (TBI) were enrolled 
from a clinical study at the Neurointensive Care Unit (NICU) at the Sahlgrenska 
University Hospital, Gothenburg, Sweden. All patients had severe TBI according to 
the following criteria: 1) Reaction Level Scale (RLS) 4, corresponding to a score of 8 
on the Glasgow Coma Scale (1); 2) were in need on ventilator treatment and; 3) 
monitoring of intracranial pressure (ICP). Venous blood samples were taken on serial 
days after trauma. Patients were treated following a standardized scheme, ‘‘the Lund 
concept’’, with the aim to maintain cerebral perfusion pressure above 60 mm Hg and 
the intracranial pressure of below 20 mm Hg (2). The study was approved by the 
Ethics Committee at University of Gothenburg; informed consent was obtained from 
the closest relative.  
 
DNA processing 
Cell free DNA was isolated using a kit (Qiaquick, Qiagen), and treated with bisulfite 
(kit details). Bisulfite treated was PCR amplified, using primers specific for bisulfite-
treated DNA but independent of methylation status. Primers were bar-coded, allowing 
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Legend to supplemental figures 
 
Figure S1: flow chart of method to detect circulating DNA derived from a specific 
tissue. 
A, procedure to identify tissue-specific methylation markers. 
B, procedure to determine levels of tissue-specific DNA in plasma. 
 
Figure S2: methylation of the insulin gene promoter in the plasma of healthy 
volunteers and recently diagnosed T1D patients. 
A, methylation status of individual CpG sites 
B, methylation status of an expanded window of 4-6 CpGs  
 
Figure S3: methylation of the MBP3 gene promoter. 
A, methylation status of the individual CpG site at the MBP3 gene promoter that is 
captured in the Illumina 450k array. Data from publicly available 450k arrays.  
B, methylation status of individual CpG sites and expanded window of multiple CpGs 
from the MBP3 gene promoter, in multiple tissues, as determined by deep sequencing. 
C, methylation of individual CpG sites from the MBP3 gene promoter in the plasma 
of healthy controls and relapsing MS/NMO patients. 
D,  fraction of fully unmethylated MBP3 promoter fragment in the plasma of healthy 
volunteers and MS/NMO patients.  
 
Figure S4: methylation of CG10809560 and adjacent CpG sites (the WM1 locus). 
A, methylation status of CG10809560 in multiple tissues as recorded in publicly 
available Illumina 450k arrays. 
B, methylation status of individual CpG sites and expanded window of multiple CpGs 
from the WM1 locus, in multiple tissues, as determined by deep sequencing. 
C, methylation of individual CpG sites from the WM1 locus in the plasma of healthy 
controls and relapsing MS/NMO patients. 
D,  fraction of fully unmethylated WM1 DNA fragments in the plasma of healthy 
volunteers and MS/NMO patients.  
 
Figure S5: methylation of CG0978 and adjacent CpG sites. 
A, methylation status of CG0978 in multiple tissues as recorded in publicly available 
Illumina 450k arrays. 
B, methylation status of individual CpG sites and expanded window of multiple CpGs 
from the CG0978 locus, in multiple tissues, as determined by deep sequencing. 
C, methylation of individual CpG sites from the CG0978 locus in the plasma of 
healthy controls and patients after cardiac arrest. 
D, fraction of fully unmethylated CG0978 DNA fragments in the plasma of healthy 
volunteers and patients after cardiac arrest.  
  
 
Figure S6: comparison of total cfDNA and brain-derived cfDNA in the plasma of 






Additional supplemental figures / tables: 
 
Must have (?): 
Clinical data on patients (recently diagnosed T1D patients, islet graft recipients, 
MS/NMO patients, cardiac arrest, TBI patients. 
 
Hopefully: 
Methylation of wrong markers as control. 
- unmethylated insulin promoter DNA in plasma of patients with brain 
pathologies 
- unmethylated MBP3 in plasma of patients with recently diagnosed type 1 
diabetes 
- unmethylated CG0978 in plasma of patients with recently diagnosed type 1 
diabetes and MS/NMO patients. 
 
